ArticleMediators of inflammation2026
Wenyang Decoction Ameliorates DSS-Induced Ulcerative Colitis by Regulating Macrophage Polarization and the PI3K/AKT/mTOR/HIF-1α Signaling Pathway.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanism Through Which Antioxidant Polysaccharide fromMolecules (Basel, Switzerland) · 2026Article
- Wenyang Decoction Ameliorates DSS-Induced Ulcerative Colitis by Regulating Macrophage Polarization and the PI3K/AKT/mTOR/HIF-1α Signaling Pathway.Mediators of inflammation · 2026Article
- Qingzhu granule mitigates acute gouty arthritis through HIF-1α-dependent glycolytic metabolic reprogramming of M1 macrophages.Frontiers in immunology · 2026Article
- Unraveling the pleiotropic roles of the mTOR-glycolytic axis in ulcerative colitis: from immunometabolic dysregulation to mucosal barrier remodeling.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by intestinal inflammation and epithelial damage. This study aims to investigate the therapeutic effects of Wenyang decoction (WYD) in a dextran sulfate sodium (DSS)-induced UC model and its underlying mechanisms, with a focus on macrophage polarization and the regulation of the PI3K/AKT/mTOR/HIF-1α signaling pathway. Methods: A DSS-induced UC model was established in C57BL/6 mice. Treatment groups received WYD at low (8.25 g/kg/day), medium (16.50 g/kg/day), or high (33.00 g/kg/day) doses, with 5-aminosalicylic acid (5-ASA, 200 mg/kg) as a positive control. Assessments included disease activity index (DAI), colon length, histopathology, and levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) and oxidative stress markers (SOD, CAT, and MDA). Mechanisms were probed using western blot, qPCR, immunofluorescence, and flow cytometry to analyze macrophage phenotypes (M1/M2) and key signaling pathway proteins. Results: WYD administration dose-dependently alleviated UC symptoms, significantly mitigating body weight loss, reducing DAI scores, and restoring colon length. Histological analysis revealed improved mucosal integrity and reduced inflammatory infiltration. Quantitatively, WYD significantly suppressed pro-inflammatory cytokines (e.g, IL-1β, IL-6, and TNF-α) and attenuated oxidative stress by enhancing antioxidant enzyme activities (SOD and CAT) and decreasing MDA content. Mechanistically, WYD inhibited M1 macrophage polarization (evidenced by downregulation of inducible nitric oxide synthase [iNOS] and CD16/32) and promoted M2 polarization (upregulation of Arg-1 and CD206). Furthermore, WYD treatment significantly inhibited the activation of the PI3K/AKT/mTOR pathway and its downstream target, HIF-1α, both in vivo and in LPS-stimulated RAW264.7 cells. Conclusion: In summary, our findings indicate that WYD exerts significant therapeutic effects in DSS-induced UC. WYD alleviates intestinal inflammation and injury by reshaping macrophage polarization, attenuating oxidative stress, and modulating the PI3K/AKT/mTOR/HIF-1α signaling pathway. This study provides a potential therapeutic strategy for UC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.